Kidney Disease Patient Representation in Trials of Combination Therapy With VEGF-Signaling Pathway Inhibitors and Immune Checkpoint Inhibitors: A Systematic Review

• Benjamin M.P. Elyan, MBChB,
• Stephen Rankin, MBChB,
• Rob Jones, PhD,
• Ninian N. Lang, PhD,
• Patrick B. Mark, PhD,
• Jennifer S. Lees, PhD

Affiliations

Benjamin M.P. Elyan, MBChB

School of Cardiovascular and Metabolic Health, College of Medical and Veterinary Life Sciences, University of Glasgow, Glasgow, UK; NHS Greater Glasgow and Clyde, Glasgow, UK; Address for Correspondence: Benjamin Elyan MBChB, BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, 126 University Avenue, Glasgow, G12 8TA.

Stephen Rankin, MBChB

School of Cardiovascular and Metabolic Health, College of Medical and Veterinary Life Sciences, University of Glasgow, Glasgow, UK; NHS Greater Glasgow and Clyde, Glasgow, UK

Rob Jones, PhD

NHS Greater Glasgow and Clyde, Glasgow, UK; School of Cancer Sciences, College of Medical and Veterinary Life Sciences, University of Glasgow, Glasgow, UK

Ninian N. Lang, PhD

School of Cardiovascular and Metabolic Health, College of Medical and Veterinary Life Sciences, University of Glasgow, Glasgow, UK; NHS Greater Glasgow and Clyde, Glasgow, UK

Patrick B. Mark, PhD

School of Cardiovascular and Metabolic Health, College of Medical and Veterinary Life Sciences, University of Glasgow, Glasgow, UK; NHS Greater Glasgow and Clyde, Glasgow, UK

Jennifer S. Lees, PhD

School of Cardiovascular and Metabolic Health, College of Medical and Veterinary Life Sciences, University of Glasgow, Glasgow, UK; NHS Greater Glasgow and Clyde, Glasgow, UK